Hormone Therapy Dosing and Selection in Menopause

Initial Dosing Strategy

• Begin menopause hormone therapy (MHT) with ultra‑low or low‑dose estrogen formulations to minimize adverse effects while preserving efficacy in relieving vasomotor symptoms. Typical starting doses include oral estradiol 0.5 mg or transdermal estradiol 0.25 mg daily. 1, 2

Route Selection and Cardiovascular Risk

• Prefer transdermal estradiol over oral estrogen for most women, especially those with cardiovascular risk factors, because the transdermal route has a more favorable impact on coagulation and thrombotic risk. 1, 2
• In women with moderate cardiovascular risk, prescribe transdermal estradiol combined with micronized progesterone (or another metabolically neutral progestogen) when the uterus is intact. 2
• In women with high cardiovascular risk, avoid systemic MHT altogether and use non‑hormonal therapies for menopausal symptoms. 2

Progestogen Selection for Women with an Intact Uterus

• Add micronized progesterone—or another metabolically neutral progestogen—to any estrogen regimen in women who have a uterus, to protect the endometrium while minimizing breast‑related side effects. 2

Age, Timing, and Baseline Risk Assessment

• Initiate MHT only in women younger than 60 years or within 10 years of menopause onset to achieve the most favorable benefit‑risk balance. 1, 2
• Perform a baseline cardiovascular disease risk assessment before starting therapy in all women, regardless of age, to guide individualized treatment decisions. 2

Management of Genitourinary Symptoms

• For isolated genitourinary syndrome of menopause, use low‑dose vaginal estrogen rather than systemic therapy; this provides effective local estrogenization with minimal systemic absorption and avoids systemic risks. 1

Safety, Regulatory, and Practical Considerations

• Use only FDA‑approved hormone preparations; avoid custom‑compounded hormones because they lack standardized dosing and quality assurance. 1, 2
• Do not initiate systemic MHT in women older than 60 years or more than 10 years post‑menopause without a thorough cardiovascular risk assessment. 1, 2

Guideline Recommendations for Hormone Therapy Eligibility and Safety in Postmenopausal Women

Eligibility Assessment

• Screen for absolute contraindications before initiating hormone therapy, including current, past, or suspected breast cancer; estrogen‑sensitive malignancies; active or recent venous thromboembolism (deep‑vein thrombosis or pulmonary embolism); active or recent arterial thromboembolic disease (myocardial infarction or angina); active liver disease; and porphyria cutanea tarda. – American College of Endocrinology & American Association of Clinical Endocrinologists 3
• Perform a comprehensive cardiovascular‑risk assessment (lipid profile, smoking status, diabetes history, and family history) to stratify individual risk prior to therapy. – American College of Endocrinology & American Association of Clinical Endocrinologists 3

Hormone‑Therapy Composition

• In women who have undergone hysterectomy, prescribe estrogen alone without a progestogen. – American College of Endocrinology & American Association of Clinical Endocrinologists 3

Cardiovascular Risk Counseling

• Counsel patients that smoking markedly increases the risk of cardiovascular events and venous thromboembolism when taking estrogen, and advise aggressive smoking cessation. – American College of Endocrinology & American Association of Clinical Endocrinologists 3
• Inform patients that cerebrovascular accidents (stroke) occur more frequently with estrogen therapy in an age‑dependent manner. – American College of Endocrinology & American Association of Clinical Endocrinologists 3
• State that hormone therapy is not indicated for primary or secondary prevention of cardiovascular disease. – American College of Endocrinology & American Association of Clinical Endocrinologists 3

Regulatory and Safety Guidance

• Use only FDA‑approved hormone preparations; avoid custom‑compounded hormones because they lack standardized dosing and quality assurance. – American College of Endocrinology & American Association of Clinical Endocrinologists 3

Management of Hot Flashes and Vulvovaginal Pruritus in Postmenopausal Women

First‑Line Hormonal Therapy

• Systemic menopausal hormone therapy (estrogen ± progestogen) is recommended as the initial treatment for moderate‑to‑severe hot flashes in women without contraindications; topical vaginal estrogen should be used for associated vulvovaginal pruritus regardless of systemic therapy status. (American College of Endocrinology & American Association of Clinical Endocrinologists – expert consensus; FDA‑approved) 4, 5, 6
• Estrogen‑containing products are the most effective FDA‑approved therapies for moderate‑to‑severe vasomotor symptoms. (ACE & AACE – high‑level evidence from regulatory approval) 4, 5, 6

Contraindications & Safety Screening

• Absolute contraindications to menopausal hormone therapy include:
  (ACE & AACE – expert consensus) 6, 4
• Before initiating therapy, assess cardiovascular risk factors (lipid panel, smoking history, diabetes, family history). (ACE & AACE – expert consensus) 6
• Counsel patients that smoking markedly increases cardiovascular and venous thromboembolic risk when taking estrogen; aggressive smoking cessation is advised. (ACE & AACE – expert consensus) 6
• Estrogen therapy is associated with an age‑dependent increase in cerebrovascular accident risk; risk rises with older age at initiation. (ACE & AACE – expert consensus) 6
• Menopausal hormone therapy is not recommended for primary or secondary prevention of cardiovascular disease. (ACE & AACE – expert consensus) 6

Topical Vaginal Estrogen for Genitourinary Symptoms

• Topical vaginal estrogen preparations are the first‑line therapy for vulvovaginal itching, dryness, and burning in postmenopausal women, irrespective of systemic hormone use. (ACE & AACE – expert consensus) 4, 5, 6
• Systemic hormone therapy should not be prescribed solely for vulvovaginal symptoms when low‑dose topical vaginal estrogen can provide effective local treatment with minimal systemic exposure. (ACE & AACE – expert consensus) 4, 5, 6

Modifiable Lifestyle Factors that Influence Hot Flashes

• Lifestyle modifications that reduce hot‑flash frequency include:
  (ACE & AACE – expert consensus; observational data) 4, 5

Hormone Therapy Dosing for Moderate‑to‑Severe Hot Flashes in Women with an Intact Uterus

Estrogen Initiation and Dosing

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend starting the lowest effective estrogen dose to control hot‑flash symptoms while minimizing adverse effects. Oral micronized 17β‑estradiol 0.5–1 mg daily, conjugated equine estrogens 0.3–0.625 mg daily, or ethinyl estradiol 0.01–0.02 mg daily are appropriate oral options. Transdermal estradiol 25–100 µg daily (patch changed twice weekly) or topical estradiol gel/emulsion/spray are suitable non‑oral options. (Evidence: guideline consensus) 7

• For women with a uterus experiencing moderate‑to‑severe hot flashes, the guideline advises oral estradiol 0.5–1 mg daily or transdermal estradiol 25–50 µg daily combined with micronized progesterone 200 mg orally for 12–14 days per month (sequential regimen) or 100 mg daily continuously. (Evidence: guideline consensus) [7][8]

Progestogen Requirement and Dosing

• Progestogen is mandatory in any woman with an intact uterus to prevent estrogen‑induced endometrial hyperplasia and cancer. (Evidence: guideline consensus) [7][8]9

• Sequential (cyclic) regimen: Micronized progesterone 200 mg orally daily for 12–14 days each month (minimum 10–12 days). (Evidence: guideline consensus) [7][10]

• Continuous combined regimen: Micronized progesterone 100 mg orally daily throughout the month to achieve amenorrhea after 6–12 months. (Evidence: guideline consensus) [7][10]

Alternative Synthetic Progestins (if micronized progesterone unavailable)

• Medroxyprogesterone acetate – 2.5 mg daily continuously or 5 mg for 10–12 days per month. (Evidence: guideline consensus) 10
• Norethindrone acetate – 0.35 mg daily continuously or 5 mg for 10–12 days per month. (Evidence: guideline consensus) 10

Monitoring and Follow‑up

• The guideline recommends re‑evaluating the decision to continue hormone therapy at least annually, aiming for the shortest duration that meets the patient’s symptom‑control goals. (Evidence: guideline consensus) 11

• Follicle‑stimulating hormone (FSH) levels should not be used to monitor therapy adequacy, because FSH remains elevated even when tissue effects are sufficient. (Evidence: guideline consensus) 10

• Lipid profile and cardiovascular risk factors should be assessed annually while on therapy. (Evidence: guideline consensus) 10

Safety‑Related Prescribing Rules (cited)

• Estrogen alone must never be prescribed to women with a uterus, as unopposed estrogen leads to endometrial hyperplasia and cancer. (Evidence: guideline consensus) [7][8]9

• Systemic hormone therapy should not be used solely for vulvovaginal symptoms; low‑dose vaginal estrogen is the preferred approach. (Evidence: guideline consensus) 11